Trump的2025年命令通过终止缉毒署的拖延、援助像MMJ生物药厂这样的公司,解除了大麻医学研究的阻塞。 Trump’s 2025 order unblocks medical marijuana research by ending DEA delays, aiding companies like MMJ BioPharma.

2025年9月15日, 特朗普总统发布第14192号行政命令, 解散缉毒署使用停滞规则作为借口, 拖延医用大麻研究, On September 15, 2025, President Trump’s Executive Order 14192 dismantled the DEA’s use of stalled rulemakings as excuses for delaying medical marijuana research, clearing the way for FDA-regulated cannabis trials. 移动给MMJ生物药厂等公司带来好处,该公司拥有林业发展局的孤儿药品标识和一个符合要求的设施,但面临多年的官僚拖延。 The move benefits companies like MMJ BioPharma, which has FDA Orphan Drug Designations and a compliant facility but faced years of bureaucratic delays. 尽管DEA承认其法庭制度违宪和内部失败,但Aarathi Haig律师 -- -- 与捍卫有缺陷的程序有关联,面临纪律问题,包括不遵守律师协会规定 -- -- 仍然积极代表该机构出庭。 Despite the DEA admitting its tribunal system was unconstitutional and internal failures, attorney Aarathi Haig—linked to defending flawed processes and facing disciplinary issues including non-compliance with bar requirements—remains active in representing the agency in court. 批评者质疑缉毒署署长Terry Cole(Terry Cole)的改革是否可信, 他现在面临压力, 要求批准长期拖延的应用程序, Critics question the credibility of reforms under DEA Administrator Terry Cole, who now faces pressure to approve long-delayed applications and uphold the administration’s directive on patient access and scientific progress.